Santen Pharmaceutical Co., Ltd. provided consolidated earnings forecasts for the fiscal year ending March 31, 2025. For the year, on a core basis, the company expects revenue of ¥297,000 million, core operating profit of ¥55,000 million, core net profit for the year of ¥41,250 million and basic core earnings per share of ¥117.05. On IFRS basis, the company expects revenue of ¥297,000 million, operating profit of ¥44,500 million, net profit for the year of ¥33,500 million and basic earnings per share of ¥92.22.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,592 JPY | +1.37% |
|
-0.99% | +13.35% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.35% | 3.64B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+1.27% | 225B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- 4536 Stock
- News Santen Pharmaceutical Co., Ltd.
- Santen Pharmaceutical Co., Ltd. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2025